Literature DB >> 16951142

Tumor cell radiosensitivity is a major determinant of tumor response to radiation.

Leo E Gerweck1, Shashirekha Vijayappa, Akihiro Kurimasa, Kazuhiko Ogawa, David J Chen.   

Abstract

Substantial evidence suggests that the radiosensitivity of the tumor cells is the primary determinant of tumor response to radiation. More recent studies suggest that tumor stroma radiosensitivity is the principle determinant of response. To assess the relationship between intrinsic tumor cell radiosensitivity and tumor response, we altered the intrinsic radiosensitivity of a cloned tumor cell line and analyzed the effect of this alteration on tumor response. A cloned tumor cell line derived from DNA double-strand break repair--deficient severe combined immunodeficient mice was transfected with the double-strand break repair gene DNA-PKcs. The intrinsic radiosensitivity of the transfected tumor line was decreased by a factor of approximately 1.5. The isogenic lines were used to initiate tumors in NCr-nu/nu mice. When transplanted in the same strain of mice and exposed to the same dose of radiation, the isogenic tumors may be expected to exhibit a similar response to radiation if radiation damage to host stroma is the principle determinant of response. This was not observed. Over the dose range of 20 Gy in four 5-Gy fractions to a single dose of 30 Gy, the 1.5-fold increase in intrinsic tumor cell radioresistance conferred by the introduction of DNA-PKcs caused a 1.5-fold decrease in tumor growth delay. The results show that the intrinsic radiosensitivity of tumor cells is a major determinant of tumor response to radiation.

Entities:  

Mesh:

Year:  2006        PMID: 16951142     DOI: 10.1158/0008-5472.CAN-06-0533

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited.

Authors:  Mónica García-Barros; Tin Htwe Thin; Jerzy Maj; Carlos Cordon-Cardo; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma.

Authors:  Wende Li; Yujiao Liu; Weining Yang; Xiaoxing Han; Sen Li; Hao Liu; Leo E Gerweck; Dai Fukumura; Jay S Loeffler; Burton B Yang; Rakesh K Jain; Peigen Huang
Journal:  J Neurooncol       Date:  2017-10-28       Impact factor: 4.130

3.  Spontaneous nonthymic tumors in SCID mice.

Authors:  Peigen Huang; Susan V Westmoreland; Rakesh K Jain; Dai Fukumura
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

Review 4.  Establishing the Impact of Vascular Damage on Tumor Response to High-Dose Radiation Therapy.

Authors:  Katherine D Castle; David G Kirsch
Journal:  Cancer Res       Date:  2019-08-19       Impact factor: 12.701

5.  MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.

Authors:  Francesco Marampon; Giovanni Luca Gravina; Agnese Di Rocco; Pierluigi Bonfili; Mario Di Staso; Caterina Fardella; Lorella Polidoro; Carmela Ciccarelli; Claudio Festuccia; Vladimir M Popov; Richard G Pestell; Vincenzo Tombolini; Bianca Maria Zani
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

6.  Development and validation of a novel assay to identify radiosensitizers that target nucleophosmin 1.

Authors:  Narsimha R Penthala; Peter A Crooks; Michael L Freeman; Konjeti R Sekhar
Journal:  Bioorg Med Chem       Date:  2015-04-11       Impact factor: 3.641

7.  Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy.

Authors:  Everett J Moding; Katherine D Castle; Bradford A Perez; Patrick Oh; Hooney D Min; Hannah Norris; Yan Ma; Diana M Cardona; Chang-Lung Lee; David G Kirsch
Journal:  Sci Transl Med       Date:  2015-03-11       Impact factor: 17.956

Review 8.  Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.

Authors:  Everett J Moding; Yvonne M Mowery; David G Kirsch
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

9.  The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines.

Authors:  L R de Moura; J-C Marshall; S Di Cesare; B F Fernandes; E Antecka; M N Burnier
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

Review 10.  Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cell Cycle       Date:  2009-04-04       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.